Product image of Micofenolato De Mofetilo Aristo (Mycophenolate Mofetil) supplied by GNH India

Micofenolato De Mofetilo Aristo

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Micofenolato De Mofetilo Aristo (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetilo Aristo, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis in appropriate patients.

GNH India supplies Micofenolato De Mofetilo Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Manufacturer / TM Owner

Aristo Pharma Iberia, S.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mycophenolate Mofetil is used in several immunologically mediated conditions, primarily to reduce graft rejection and renal inflammation.
  • Kidney transplant rejection: helps prevent organ rejection in kidney transplant recipients.
  • Heart transplant rejection: helps prevent organ rejection in heart transplant recipients.
  • Liver transplant rejection: helps prevent organ rejection in liver transplant recipients.
  • Lupus nephritis: reduces kidney inflammation in patients with systemic lupus erythematosus.

How It Works

  • Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively and reversibly inhibits inosine monophosphate dehydrogenase (IMPDH). This inhibition depletes guanosine nucleotides, impairing DNA synthesis and proliferation of activated T and B lymphocytes, thereby attenuating the immune response that drives graft rejection and autoimmune renal injury.

Side Effects

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: frequent loose stools.
  • Vomiting: occasional emesis.
  • Abdominal pain: cramping or discomfort.
  • Headache: transient head pain.
  • Infections: increased susceptibility to bacterial, viral or fungal infections.

Serious or Rare Side Effects

  • Leukopenia: significant reduction in white blood cells.
  • Anemia: decreased red blood cell count.
  • Severe infections: opportunistic or life‑threatening infections.
  • Malignancy: increased risk of certain cancers.
  • Hepatic toxicity: elevated liver enzymes or hepatitis.
  • Progressive multifocal leukoencephalopathy: rare demyelinating brain disease.

Precautions & Warnings

  • Patients receiving Mycophenolate Mofetil should be monitored closely for safety concerns.
  • Monitor blood counts: perform regular CBC to detect leukopenia or anemia.
  • Assess renal function: adjust dose in renal impairment and monitor creatinine.
  • Avoid live vaccines: immunosuppression can render live vaccines unsafe.
  • Pregnancy: drug is category D; avoid unless benefits outweigh risks.
  • Store at below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Mycophenolate Mofetil interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid)

  • Azathioprine: additive bone‑marrow suppression.
  • Cyclosporine: increased mycophenolate exposure, raising toxicity risk.
  • Rituximab: heightened infection risk when combined.

Moderate Interactions (Monitor Closely)

  • Antacids containing aluminum or magnesium: may reduce absorption of mycophenolic acid.
  • Live‑attenuated vaccines: monitor immune response and infection risk.
  • Warfarin: possible effect on INR; require more frequent coagulation monitoring.

Frequently Asked Questions

Micofenolato De Mofetilo Aristo contains mycophenolate mofetil, which is prescribed to prevent rejection of kidney, heart, and liver transplants and to treat lupus nephritis, a kidney manifestation of systemic lupus erythematosus.

Mycophenolate mofetil is converted to mycophenolic acid, which blocks the enzyme inosine monophosphate dehydrogenase (IMPDH). This stops the synthesis of guanosine nucleotides, limiting the proliferation of activated T and B lymphocytes and thereby suppressing the immune response.

The appropriate dose is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and other individual factors. Only a qualified healthcare professional should set the dosing regimen.

Mycophenolate mofetil is classified as pregnancy category D, indicating evidence of risk to the fetus. It should be avoided in pregnancy unless the potential benefit justifies the risk, and breastfeeding is generally not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, mycophenolate mofetil offers a different mechanism—IMPDH inhibition—resulting in less nephrotoxicity but a higher propensity for bone‑marrow suppression and gastrointestinal upset. Choice of therapy depends on the transplant protocol and patient tolerance.

The product should be stored at or below 25 °C, protected from moisture and light, and kept in its original packaging until use. Do not store in a refrigerator or freezer unless the label specifically indicates otherwise.

Micofenolato De Mofetilo Aristo is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The exact schedule—once or twice daily—depends on the prescribing clinician’s instructions.

Serious risks include severe bone‑marrow suppression (leukopenia, anemia), opportunistic infections, increased risk of certain malignancies, hepatic toxicity, and rare neurological complications such as progressive multifocal leukoencephalopathy. Patients should be monitored regularly for these events.

Patients with known hypersensitivity to mycophenolate mofetil or any component of the formulation should avoid the drug. It is also contraindicated in pregnant women unless absolutely necessary, and in individuals with severe, uncontrolled infections or significant bone‑marrow failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT